Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II

Circulation

Volumn 98, Issue 8, 1998, Pages 794-799

  Nakamura, Kazufumi ^a   Fushimi, Kazuo ^b   Kouchi, Hirosuke ^b   Mihara, Koichiro ^b   Miyazaki, Masahiro ^b   Ohe, Tohru ^b   Namba, Masayoshi ^b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Antioxidants; Cells; Growth substances; Hypertrophy; Myocytes

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; ANTIOXIDANT; BUTYLATED HYDROXYANISOLE; CATALASE; FLUORESCEIN DIACETATE; LEUCINE; REACTIVE OXYGEN METABOLITE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TRITIUM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032566405     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.8.794     Document Type: Article

References (38)

1. Opie LH. Ventricular hypertrophy and its molecular biology. The Heart: Physiology and Metabolism. New York, NY: Raven Press; 1991:369-395.
2. Chien KR. Molecular advances in cardiovascular biology. Science. 1993; 260:916-917.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
4. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med. 1987;317:787-792.
5. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60:560-565.
6. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
7. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
8. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
9. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
10. Gilbert EM, Bristow MR. Idiopathic dilated cardiomyopathy. In: Schlant RC, Alexander RW, eds. Hurst's The Heart: Arteries and Veins. New York, NY: McGraw-Hill Inc; 1994:1609-1619.
11. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89: 151-163.
12. Long CS, Henrich CJ, Simpson PC. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell Regul. 1991;2:1081-1095.
13. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247-1252.
14. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res. 1993;73: 413-423.
15. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990;259:H610-H618.
16. Matthews N, Neale ML, Jackson SK, Stark JM. Tumor cell killing by tumor necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology. 1987;62:153-155.
17. Wong GHW, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 1989;58:923-931.
18. Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci U S A. 1995;92: 8115-8119.
19. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593.
20. Wen Y, Scott S, Liu Y, Gonzales N, Nadler JL. Evidence that angiotensin II and lipoxygenase products activate c-Jun NH2-terminal kinase. Circ Res. 1997;81:651-655.
21. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992;70: 593-599.
22. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-1874.
23. Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J. 1997;11:118-124.
24. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun · c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem. 1995;270:22129-22134.
25. Laderoute KR, Webster KA. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ Res. 1997;80:336-344.
26. 2 for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
27. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an α1-adrenergic receptor and induction of beating through an α1- and β1-adrenergic receptor interaction. Circ Res. 1985;56:884-894.
28. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol. 1983;130: 1910-1917.
29. Cathcart R, Schwiers E, Ames BN. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal Biochem. 1983;134:111-116.
30. Zhu H, Bannenberg GL, Moldeus P, Schertzer HG. Oxidation pathways for the intracellular probe 2′,7′-dichlorofluorescin. Arch Toxicol. 1994; 68:582-587.
31. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest. 1995;96:1093-1099.
32. Liebler DC. The role of metabolism in the antioxidant function of vitamin E. Crit Rev Toxicol. 1993;23:147-169.
33. Kamal-Eldin A, Appelqvist LA. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids. 1996;31:671-701.
34. Martin A, Zulueta J, Hassoun P, Blumberg JB, Meydani M. Effect of vitamin E on hydrogen peroxide production by human vascular endothelial cells after hypoxia/reoxygenation. Free Radic Biol. Med. 1996;20: 99-105.
35. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527-605.
36. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro: roles of phospholipid-derived second messengers. Circ Res. 1993;73:424-438.
37. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T, Yazaki Y. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996;271:33592-33597.
38. 2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res. 1997;80: 139-146.